NEW YORK (GenomeWeb News) – Evotec said today that it will screen small molecule compounds for drug developer Genentech under a new collaborative agreement.
Under the multi-year alliance, Evotec will use its disease knowledgebase and drug discovery platform to test small molecule candidates for the Roche subsidiary. The research will include assay development, high-throughput screening, structural biology, and medicinal chemistry services, Hamburg-based Evotec said.